Perspective Therapeutics (NYSEAMERICAN:CATX) Hits New 1-Year High at $1.62

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) shares hit a new 52-week high on Tuesday . The stock traded as high as 1.62 and last traded at 1.60, with a volume of 1449231 shares. The stock had previously closed at 1.53.

Wall Street Analyst Weigh In

Several research analysts recently commented on CATX shares. Oppenheimer restated an "outperform" rating and issued a $1.50 price target (up previously from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st. B. Riley lifted their target price on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the company a "buy" rating in a report on Tuesday, April 9th.

Perspective Therapeutics Price Performance

The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.02. The firm has a market cap of $997.76 million, a P/E ratio of -16.65 and a beta of 1.56.

Insider Buying and Selling

In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of Perspective Therapeutics stock in a transaction dated Wednesday, March 6th. The stock was acquired at an average cost of 0.95 per share, for a total transaction of 57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares in the company, valued at approximately 110,934,724.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the firm's stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average price of 0.95 per share, for a total transaction of 57,409,487.05. Following the transaction, the insider now directly owns 116,773,394 shares of the company's stock, valued at approximately 110,934,724.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Markus Puhlmann purchased 280,000 shares of the company's stock in a transaction on Wednesday, January 24th. The shares were bought at an average price of 0.50 per share, for a total transaction of 140,000.00. Following the completion of the transaction, the insider now directly owns 1,375,425 shares in the company, valued at approximately 687,712.50. The disclosure for this purchase can be found here. Insiders have bought a total of 60,758,439 shares of company stock valued at $57,576,503 in the last quarter. Company insiders own 5.72% of the company's stock.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Taylor & Morgan Wealth Management LLC increased its holdings in shares of Perspective Therapeutics by 8.7% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company's stock valued at $251,000 after buying an additional 50,000 shares in the last quarter. HighTower Advisors LLC purchased a new position in Perspective Therapeutics in the 3rd quarter worth about $314,000. Perkins Capital Management Inc. acquired a new stake in Perspective Therapeutics during the 3rd quarter worth about $731,000. Finally, Bank of New York Mellon Corp purchased a new stake in Perspective Therapeutics during the third quarter valued at about $42,000. 54.66% of the stock is owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.